Ferriprox

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ Date: _____
Patient's ID: _____ Patient's Date of Birth: _____
Physician's Name: _____
Specialty: _____ NPI#: _____
Physician Office Telephone: _____ Physician Office Fax: _____
Request Initiated For: _____

1. What is the diagnosis?
   ❑ Transfusional iron overload due to a thalassemia syndrome
   ❑ Other _____
2. What is the ICD-10 code? _____
3. Is the product being requested for the treatment of chronic iron overload? ❑ Yes ❑ No *If No, skip to #9*
4. The preferred products for your patient's health plan are Exjade, Jadenu, deferoxamine, and Desferal. Can the patient's treatment be switched to a preferred product? ***If Yes, please call 1-866-814-5506 to have the updated form faxed to your office OR you may complete the PA electronically (ePA). You may sign up online via CoverMyMeds at: www.covermymeds.com/epa/caremark/ or call 1-866-452-5017.***
   ❑ Yes - Exjade ❑ Yes - Jadenu ❑ Yes - deferoxamine ❑ Yes - Desferal
   ❑ No - Continue request for Ferriprox
5. Does the patient have a documented inadequate response or intolerable adverse event to at least one preferred deferasirox product (Exjade and/or Jadenu)? ***ACTION REQUIRED: If Yes, attach supporting chart note(s).***
   If Yes, skip #7 ❑ Yes ❑ No
6. Does the patient have any of the following documented clinical reasons to avoid deferasirox products (Exjade and Jadenu)? ***ACTION REQUIRED: If Yes, attach supporting chart note(s).***
   ❑ Estimated glomerular filtration rate (GFR) less than 40 mL/min/1.73 m^2
   ❑ Poor performance status
   ❑ High-risk myelodysplastic syndrome
   ❑ Advanced malignancy
   ❑ Platelet count less than 50 x 10^9/L
   ❑ Known hypersensitivity to deferasirox or any components of Exjade and Jadenu drug formulations
   ❑ Severe (Child-Pugh C) hepatic impairment
   ❑ None of the above, *complete this form in its entirety and State Step Therapy section.*

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

7. Does the patient have a documented inadequate response or intolerable adverse event to at least one preferred deferoxamine product (generic deferoxamine and/or Desferal)? ***ACTION REQUIRED: If Yes, attach supporting chart note(s) and skip to #9.*** ❑ Yes ❑ No
8. Does the patient have any of the following documented clinical reasons to avoid deferoxamine products (deferoxamine and Desferal)? ***ACTION REQUIRED: If Yes, attach supporting chart note(s).***
   ❑ Severe renal disease ❑ Anuria ❑ Known hypersensitivity to deferoxamine
   ❑ None of the above, *complete this form in its entirety and State Step Therapy section.*
9. Is this a request for continuation of therapy with the requested drug? ❑ Yes ❑ No *If No, skip to #12*
10. Is the patient experiencing benefit from therapy as evidenced by a decrease in serum ferritin levels as compared to pretreatment baseline? ***ACTION REQUIRED: If Yes, attach supporting laboratory report or chart notes with current serum ferritin level.*** ❑ Yes ❑ No
11. Is the patient's serum ferritin level consistently below 500 mcg/L? ❑ Yes ❑ No *No further questions*
12. Is the patient's pretreatment serum ferritin level consistently greater than 1000 mcg/L? *Note: If the patient is currently on therapy for iron overload, provide the patient's serum ferritin level before patient initiated therapy.* ***ACTION REQUIRED: If Yes, attach supporting laboratory report or chart notes with pretreatment serum ferritin level.*** ❑ Yes ❑ No
13. Will the dose of the requested drug exceed 99 mg/kg per day? ❑ Yes ❑ No

State Step Therapy

1. Is the requested drug being used for an FDA-approved indication or an indication supported in the compendia of current literature (examples: AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)? ❑ Yes ❑ No
2. Does the prescribed quantity fall within the manufacturer's published dosing guidelines or within dosing guidelines found in the compendia of current literature (examples: package insert, AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)? ❑ Yes ❑ No
3. Does the patient reside in Maryland? ❑ Yes ❑ No *If No, skip to #7*
4. Is the alternate drug (Exjade, Jadenu, deferoxamine, Desferal) FDA-approved for the medical condition being treated? ❑ Yes ❑ No *If No, please specify:* _____
5. Has the prescriber provided proof, documented in the patient's chart notes, indicating that the requested drug was ordered for the patient in the past 180 days? ❑ Yes ❑ No *If No, skip to #7*
6. Has the prescriber provided proof, documented in the patient chart notes, that in their opinion the requested drug is effective for the patient's condition? ❑ Yes ❑ No *No further questions*
7. Are any of the following conditions met for the alternate drug (Exjade, Jadenu, deferoxamine, Desferal)?
   If Yes, indicate below and no further questions.
   ❑ The alternate drug is contraindicated
   ❑ The alternate drug is likely to cause an adverse reaction, physical or mental harm
   ❑ The alternate drug is expected to be ineffective
   ❑ The alternate drug was previously tried or a drug in the same class or with the same action was previously tried and was stopped due to ineffectiveness or an adverse event
   ❑ The alternate drug is not in the patient's best interest
   ❑ The alternate drug was tried while covered by the current or the previous health benefit plan
   ❑ None of the above
   If Yes, please specify: _____
8. Is the patient stable or currently receiving a positive therapeutic outcome with the requested drug and a change in the prescription drug is expected to be ineffective or cause harm to the patient? ❑ Yes ❑ No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

X_____
Prescriber or Authorized Signature Date (mm/dd/yy)

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155